Subtype
Childhood Central Nervous System Embryonal Tumor
CI-CAN-00000692Explore in graph →
Pediatric13 active trials2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000692Explore in graph →
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (10)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07346157 | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease(PNOC044) | recruiting | Phase 1 / Phase 2 | 69 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07390539 | B7-H3.CD28Z.CART in CNS Neoplasms | recruiting | Phase 1 | 70 | Robbie MajznerOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06193759 |
| Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)(IMPACT) |
| recruiting |
| Phase 1 |
| 12 |
| Children's National Research InstituteOTHER |
| 1 |
| Jun 17, 2026 |
| clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | terminated | Phase 1 / Phase 2 | 21 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT05298995 | GD2-CAR T Cells for Pediatric Brain Tumours | recruiting | Phase 1 | 54 | Bambino Gesù Hospital and Research InstituteOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT04167618 | 177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma | terminated | Phase 1 / Phase 2 | 2 | Y-mAbs TherapeuticsINDUSTRY | 5 | Oct 6, 2023 | clinicaltrials |
| NCT02095132 | Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 76 | National Cancer Institute (NCI)NIH | 2 | Sep 26, 2023 | clinicaltrials |
| NCT02444546 | Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors | completed | Phase 1 | 6 | Mayo ClinicOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT00983398 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | unknown | Phase 1 / Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | terminated | Phase 1 | 35 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02271711 | Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors | completed | Phase 1 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 2, 2020 | clinicaltrials |
| NCT00326664 | AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2016 | clinicaltrials |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia | terminated | Phase 1 | 129 | National Cancer Institute (NCI)NIH | 2 | Nov 5, 2014 | clinicaltrials |
| NCT00946335 | ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors | completed | Phase 1 | 31 | National Cancer Institute (NCI)NIH | 1 | Jul 9, 2014 | clinicaltrials |
| NCT00217412 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 17, 2014 | clinicaltrials |
| NCT00095940 | Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00822458 | GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 2, 2014 | clinicaltrials |
| NCT00387920 | Sunitinib in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 2 | Jan 28, 2014 | clinicaltrials |
| NCT00052780 | Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors | completed | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00063973 | Cilengitide in Treating Children With Refractory Primary Brain Tumors | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00100880 | Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors | completed | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT00929903 | Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment | completed | Phase 1 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2013 | clinicaltrials |
| NCT01697514 | A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma | withdrawn | Phase 1 | 0 | Eli Lilly and CompanyINDUSTRY | 1 | Aug 27, 2013 | clinicaltrials |
| NCT00012181 | Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2013 | clinicaltrials |
| NCT00077454 | Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 | 95 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00101270 | Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas | completed | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00281944 | Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | May 3, 2013 | clinicaltrials |
| NCT01076530 | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 2 | May 3, 2013 | clinicaltrials |
| NCT00053963 | FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00363272 | Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
Data updated 2 days agoSource updated Sep 28, 2026source: clinicaltrials